220 related articles for article (PubMed ID: 35262964)
1. Large-cohort humanized NPI mice reconstituted with CD34
Xu X; Gu H; Li H; Gao S; Shi X; Shen J; Li B; Wang H; Zheng K; Shao Z; Cheng P; Cha Z; Peng S; Nie Y; Li Z; Guo S; Qian B; Jin G
FASEB J; 2022 Apr; 36(4):e22244. PubMed ID: 35262964
[TBL] [Abstract][Full Text] [Related]
2. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses.
Meraz IM; Majidi M; Meng F; Shao R; Ha MJ; Neri S; Fang B; Lin SH; Tinkey PT; Shpall EJ; Morris J; Roth JA
Cancer Immunol Res; 2019 Aug; 7(8):1267-1279. PubMed ID: 31186248
[TBL] [Abstract][Full Text] [Related]
3. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma.
Luo W; Hoang H; Liao Y; Pan J; Ayello J; Cairo MS
Front Immunol; 2023; 14():1277987. PubMed ID: 37868989
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
5. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
7. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
8. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
[TBL] [Abstract][Full Text] [Related]
9. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.
Verma B; Wesa A
Curr Protoc Pharmacol; 2020 Jun; 89(1):e77. PubMed ID: 32453514
[TBL] [Abstract][Full Text] [Related]
10. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
12. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
13. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
14. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
[TBL] [Abstract][Full Text] [Related]
15. Humanized mice are precious tools for evaluation of hematopoietic gene therapies and preclinical modeling to move towards a clinical trial.
Brendel C; Rio P; Verhoeyen E
Biochem Pharmacol; 2020 Apr; 174():113711. PubMed ID: 31726047
[TBL] [Abstract][Full Text] [Related]
16. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of the efficacy of an antibody to human SIRPα for cancer immunotherapy in humanized mouse models.
Saito Y; Iida-Norita R; Afroj T; Refaat A; Hazama D; Komori S; Ohata S; Takai T; Oduori OS; Kotani T; Funakoshi Y; Koma YI; Murata Y; Yakushijin K; Matsuoka H; Minami H; Yokozaki H; Manz MG; Matozaki T
Front Immunol; 2023; 14():1294814. PubMed ID: 38162643
[TBL] [Abstract][Full Text] [Related]
18. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.
Shi N; Zhou Y; Liu Y; Zhang R; Jiang X; Ren C; Gao X; Luo L
Front Immunol; 2022; 13():1047610. PubMed ID: 36518768
[TBL] [Abstract][Full Text] [Related]
19. Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Odunsi A; McGray AJR; Miliotto A; Zhang Y; Wang J; Abiola A; Eppolito C; Huang RY
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177175
[TBL] [Abstract][Full Text] [Related]
20. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.
Jin CH; Xia J; Rafiq S; Huang X; Hu Z; Zhou X; Brentjens RJ; Yang YG
EBioMedicine; 2019 Jan; 39():173-181. PubMed ID: 30579863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
